收藏切换
The complete response letter in FDA's review decision feedback mechanism and its implications for China
收藏切换
Jian LU, Ming-quan SHA, Mei-yi DONG, Yu BAI*
Chinese Journal of New Drugs | 2026, 35(7) : 695 - 700
Less
收藏切换
Chinese Journal of New Drugs | 2026, 35(7): 695-700
The complete response letter in FDA's review decision feedback mechanism and its implications for China
Full
Jian LU, Ming-quan SHA, Mei-yi DONG, Yu BAI*
Affiliations
  • Center for Drug Evaluation, China National Drug Administration, Beijing 100076, China
Published: 2026-04-15 doi: 10.20251/j.cnki.1003-3734.2026.07.004
Outline
收藏切换

By sorting out the development history, specific content, institutional advantages, and challenges of the complete response letter system in the U.S. evaluation decision feedback mechanism, as well as the current situation of drug evaluation feedback mechanism in China, suggestions for China's evaluation decision feedback mechanism were put forward. The U.S. complete response letter system has certain institutional advantages in improving the transparency of evaluation and guiding applicants' subsequent research and development, thereby contributing to the advancement of the U.S. pharmaceutical industry. China needs to carry out appropriate transformation in combination with its own regulatory practices and external environment. For innovative drugs and other drugs with clinical application prospects, on the premise of informing applicants of "why it is not feasible", further guidance should be provided on "what to do next”; internal evaluation procedures should be optimized to improve the continuity of evaluation; common reasons for rejection of approval should be summarized regularly to provide experience for applicants, avoiding repeated detours; public laws and regulations should be gradually improved to achieve a balance between "disclosure" and "protection”. This article provides references for improving the feedback mechanism of drug evaluation and decision-making in China.

drug review  /  complete response letter  /  openness and transparency
陆建, 沙明泉, 董美意, 白玉. 美国FDA药品审评决策反馈机制中完整回复函制度对我国药品监管的启示. 中国新药杂志, 2026 , 35 (7) : 695 -700 . DOI: 10.20251/j.cnki.1003-3734.2026.07.004
Jian LU, Ming-quan SHA, Mei-yi DONG, Yu BAI. The complete response letter in FDA's review decision feedback mechanism and its implications for China[J]. Chinese Journal of New Drugs, 2026 , 35 (7) : 695 -700 . DOI: 10.20251/j.cnki.1003-3734.2026.07.004
Year 2026 volume 35 Issue 7
30
6
Cite this Article
BibTeX
Article Info
doi: 10.20251/j.cnki.1003-3734.2026.07.004
  • Online Date:2026-10-26
  • Published:2026-04-15
Article Data
Affiliations
History
  • Accepted:2025-12-02
Affiliations
    Center for Drug Evaluation, China National Drug Administration, Beijing 100076, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/10.20251/j.cnki.1003-3734.2026.07.004
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT